Synkrino Biotherapeutics
Innovative solutions harnessing patient immune systems for breakthrough drug discovery and rapid viral screening.
Innovative solutions harnessing patient immune systems for breakthrough drug discovery and rapid viral screening.
Synkrino Biotherapeutics is a biotech platform leveraging innovative solutions to harness patient immune systems for breakthrough drug discovery and rapid viral screening. The company, founded in 2018, is dedicated to identifying and developing new drug targets directly from the immune system of patients. Its platform offers monitoring solutions for pediatric rheumatologists dealing with life-threatening conditions and is currently focused on developing a quick, portable field test for the RNA virus 2019-nCoV/COVID-19. This involves adapting its existing analytic protocols for community public health screening.
Synkrino Biotherapeutics' therapeutics are driven by the AI + Immunology Discovery Engine (AIDE Engine), which utilizes neural networks and machine learning to analyze immune tissue from patients, consistently identifying new and biologically-valid drug targets. This approach empowers healthcare providers to effectively treat their patients and enhance their quality of life.
The company received its Seed Round investment on 23 August 2018 from Endpoint Ventures. With a focus on biotechnology and health care industries, Synkrino Biotherapeutics represents a promising venture at the intersection of healthcare innovation and biotechnology.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | Unknown | 1 | Endpoint Ventures | 23 Aug 2018 |
No recent news or press coverage available for Synkrino Biotherapeutics.
We care about your data, and we'd love to use cookies make your experience better.
